Stock 000919 JINLING PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jinling Pharmaceutical Company Limited

Equities

000919

CNE0000010W5

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 15/05/2024 BST 		5-day change 1st Jan Change
7.16 CNY -0.28% Intraday chart for Jinling Pharmaceutical Company Limited -1.65% -9.02%
04-30 Jinling Pharmaceutical Company Limited Proposes Final Cash Dividend for the Year 2023 CI
04-29 Jinling Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 3,160 3,679 3,876 3,856 3,966 4,023
Enterprise Value (EV) 1 1,733 2,103 2,559 2,369 2,134 2,515
P/E ratio 13.1 x 25.3 x 59.5 x 32 x 37.2 x 39.8 x
Yield 2.71% 2.33% 1.3% 1.31% 1.29% 1.27%
Capitalization / Revenue 1.09 x 1.45 x 1.55 x 1.37 x 1.48 x 1.44 x
EV / Revenue 0.6 x 0.83 x 1.02 x 0.84 x 0.8 x 0.9 x
EV / EBITDA 5.24 x 6.9 x 8.83 x 8.27 x 12.5 x 13.2 x
EV / FCF 4.59 x 2.83 x -15,083 x 43.4 x -15.8 x -60.5 x
FCF Yield 21.8% 35.4% -0.01% 2.31% -6.32% -1.65%
Price to Book 1.15 x 1.28 x 1.36 x 1.32 x 1.27 x 1.32 x
Nbr of stocks (in thousands) 504,000 504,000 504,000 504,000 510,400 511,136
Reference price 2 6.270 7.300 7.690 7.650 7.770 7.870
Announcement Date 25/03/19 30/03/20 29/03/21 28/03/22 24/03/23 29/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 2,899 2,535 2,504 2,809 2,671 2,786
EBITDA 1 330.9 304.9 289.9 286.3 171.2 190.3
EBIT 1 210.6 186 173.7 167.6 51.03 65.24
Operating Margin 7.26% 7.34% 6.94% 5.97% 1.91% 2.34%
Earnings before Tax (EBT) 1 361.5 247.4 125.1 194.8 127.8 118.4
Net income 1 241.8 145.3 65.14 120.6 105.3 99.65
Net margin 8.34% 5.73% 2.6% 4.29% 3.94% 3.58%
EPS 2 0.4797 0.2883 0.1292 0.2393 0.2089 0.1977
Free Cash Flow 1 377.6 743.5 -0.1696 54.63 -134.9 -41.61
FCF margin 13.02% 29.33% -0.01% 1.95% -5.05% -1.49%
FCF Conversion (EBITDA) 114.09% 243.83% - 19.08% - -
FCF Conversion (Net income) 156.16% 511.64% - 45.29% - -
Dividend per Share 2 0.1700 0.1700 0.1000 0.1000 0.1000 0.1000
Announcement Date 25/03/19 30/03/20 29/03/21 28/03/22 24/03/23 29/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,427 1,576 1,317 1,486 1,832 1,507
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 378 744 -0.17 54.6 -135 -41.6
ROE (net income / shareholders' equity) 9.17% 5.51% 2.73% 4.39% 3.18% 2.93%
ROA (Net income/ Total Assets) 3.4% 2.89% 2.57% 2.4% 0.71% 0.9%
Assets 1 7,111 5,027 2,532 5,028 14,841 11,114
Book Value Per Share 2 5.430 5.710 5.670 5.810 6.120 5.950
Cash Flow per Share 2 1.920 2.910 2.610 2.980 3.060 2.800
Capex 1 136 126 291 163 310 186
Capex / Sales 4.71% 4.96% 11.64% 5.79% 11.59% 6.69%
Announcement Date 25/03/19 30/03/20 29/03/21 28/03/22 24/03/23 29/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
JINLING PHARMACEUTICAL COMPANY LIMITED Stock Jinling Pharmaceutical Company Limited
-9.02% 624M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.36% 694B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.15% 593B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.60% 371B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.07% 331B
ABBVIE INC. Stock AbbVie Inc.
+6.04% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.66% 239B
NOVARTIS AG Stock Novartis AG
+10.51% 209B
ROCHE HOLDING AG Stock Roche Holding AG
-2.78% 209B
AMGEN INC. Stock Amgen Inc.
+9.27% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 000919 Stock
  4. Financials Jinling Pharmaceutical Company Limited